drugset
drugset / Trial / NCT06364501

Phase 1 Trial of KH801

NCT06364501 ↗

Phase 1 Not yet recruiting 17 enrolled Beijing Kanghong Biopharmaceutical Co., Ltd.
NaSequentialOpen-labelTreatment

Summary

KH801 is a injection used for advanced solid tumors which must be diluted with 5% Dextrose Or 0.9% sodium chloride Injection. This study is expected to include a total of approximately 17-42 participants.

Timeline

Start
2024-09-01
Primary completion
2026-05-01
Completion
2030-05-01

Drugs

EvaluationDrugModalityDoseRoute
Subject KH801 Unknown 0.01 mg/kg Intravenous
Subject KH801 Unknown 0.1 mg/kg Intravenous
Subject KH801 Unknown 0.3 mg/kg Intravenous
Subject KH801 Unknown 1 mg/kg Intravenous
Subject KH801 Unknown 3 mg/kg Intravenous
Subject KH801 Unknown 6 mg/kg Intravenous
Subject KH801 Unknown 10 mg/kg Intravenous

Indications

cancer